NIQ Unveils New Brand Identity Reflecting Commitment to the Full View of Consumer Intelligence
1.3.2023 15:00:00 EET | Business Wire | Press release
NIQ, the global leader in consumer intelligence, has launched a new brand identity, reflecting the company’s industry-leading insights and measurement capabilities, revealing new pathways to growth for retailers and brands. The new branding aligns with a significant transformation across the organization and represents a commitment to delivering the most complete and clear understanding of consumers globally – the Full View.
NIQ’s Full View is powered by more—more data from more channels, sources, consumers, and regions. Understanding, measuring, and activating on complete data provides an unparalleled opportunity for clients to gain a competitive advantage, capitalize on opportunities, mitigate risks, and understand evolving consumer shopping behavior. With the clearest understanding of consumer behavior, delivered through an advanced platform with integrated analytics, businesses can make confident decisions that will drive growth.
“The new brand identity balances our legacy and our future as the leader in consumer intelligence,” says Tracey Massey, Chief Operating Officer, NIQ. “In 1923, our company created the concept of market share, and now, with our investments in omnichannel, NIQ’s identity signifies the new standard for understanding what consumers buy, why they make purchase decisions, and most importantly, how our clients can win.”
New elements of the brand identity include revamped company name, logo, colors, and purpose. Together, they signal the company’s evolution and signify leadership in omnichannel consumer intelligence.
- Name/Logo: NIQ, builds on the company’s legacy and reinvents itself for the future.
- Color palate: The diverse range of colors support NIQ’s advanced Connect platform and Discover data visualization platform, a robust and intuitive business intelligence tool that interacts with the most complete consumer data sets around the world.
- Brand purpose: “Show the world what people want,” focuses the company’s strategy and employee value proposition.
- Brand promise: “We deliver the Full View, the world’s most complete and clear understanding of consumer buying behavior that reveals new pathways to growth,” shows clients our uniquely ambitious point of view.
“Our new identity embodies the renewed sense of purpose, and energy across the company, that embraces change, innovation, and solves the industry's biggest challenges,” says Marta Cyhan-Bowles, Chief Communication Officer & Head of Marketing, North America. “This is a milestone year for NIQ, as the company accelerates our vision for the world to see us for who we truly are, a pathway to growth.”
NIQ’s new identity will be showcased at the annual Consumer 360® conference as the company breaks new passages towards purpose, defines new inroads for innovation, creates new bridges for collaboration, and maps new pathways to growth.
For more information about NIQ and to view the new brand identity, please visit www.niq.com.
About NIQ
NIQ, the world’s leading consumer intelligence company, reveals new pathways to growth for retailers and consumer goods manufacturers. With operations in more than 100 countries, NIQ delivers the most complete and clear understanding of consumer buying behavior through an advanced business intelligence platform with integrated predictive analytics. NIQ delivers the Full View.
NIQ was founded in 1923 and is an Advent International portfolio company. For more information, visit NIQ.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230301005477/en/
Contact information
Media
Gillian Mosher (gillian.mosher@nielseniq.com)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
